**Question:** Apixaban is a new drug that acts by:

**Core Concept:** Apixaban is a direct oral anticoagulant (DOAC), a class of medications that directly inhibit specific coagulation factors without requiring monitoring of coagulation tests. Apixaban targets Factor Xa (Factor Xa inhibitor), a key enzyme in the intrinsic pathway of blood coagulation.

**Why the Correct Answer is Right:** Apixaban inhibits Factor Xa, a key enzyme in the intrinsic pathway of blood coagulation. By doing so, it directly prevents the formation of thrombin (factor IIa) and fibrin, thereby reducing the risk of blood clot formation and preventing thromboembolic events.

**Why Each Wrong Option is Incorrect:**

A. Inhibition of Factor IIa (thrombin): Apixaban does not inhibit thrombin, but rather Factor Xa. This is why this option is incorrect.
B. Inhibition of platelet aggregation: Apixaban does not target platelets or their aggregation, unlike some antiplatelet agents like aspirin, clopidogrel, or ticagrelor.
C. Monitoring of coagulation tests: Apixaban is a direct anticoagulant, so it does not require coagulation test monitoring like vitamin K antagonists (e.g., warfarin). Apixaban works directly on Factor Xa without relying on the indirect action of warfarin on vitamin K synthesis.
D. Inhibition of fibrinolysis: Apixaban does not inhibit fibrinolysis (fibrin degradation), as its primary action is on Factor Xa and its inhibition leads to reduced thrombin generation and fibrin formation.

**Clinical Pearl:** Apixaban is one of the DOACs (direct oral anticoagulants) and is more convenient compared to vitamin K antagonists (e.g., warfarin), as it does not require routine coagulation test monitoring.

**Correct Answer:** Apixaban (D) is correct because it directly inhibits Factor Xa, reducing thrombin generation and fibrin formation, thereby preventing thromboembolic events. Apixaban does not require coagulation test monitoring, unlike vitamin K antagonists like warfarin.